69464-98-8

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
BMPPP is utilized as a reference standard in pharmaceutical research and drug development, particularly for the evaluation of its potential pharmacological activities. Its analgesic and anti-inflammatory properties make it a promising candidate for the development of new medications.
Used in Analytical Techniques:
In the field of analytical chemistry, BMPPP serves as a reference standard for techniques such as chromatography and spectrophotometry. This allows for accurate measurements and comparisons in various chemical analyses.
Used in Chemical Synthesis:
BMPPP can also be used as a building block in the synthesis of other chemical compounds, contributing to the development of new materials and products in the chemical industry.
Used in Research and Development of New Medications:
Due to its potential pharmacological activities, BMPPP is employed in the research and development of new medications, particularly those targeting pain relief and inflammation reduction.

InChI:InChI=1/C10H10BrN3/c1-7-9(11)10(12)14(13-7)8-5-3-2-4-6-8/h2-6H,12H2,1H3

Upstream product

• 60930-93-0 1-bromo-1-cyanopropan-2-on 
• 100-63-0 phenylhydrazine 
• 1131-18-6 1-Phenyl-3-methyl-5-aminopyrazole 

Downstream Products

• 77696-56-1 5-amino-4'-bromo-3,3'-dimethyl-4,5'-azobis-1,1'-diphenylpyrazole 
• 130645-90-8 (4-Bromo-5-methyl-2-phenyl-2H-pyrazol-3-yl)-[1-(4-dimethylamino-phenyl)-meth-(E)-ylidene]-amine 
• 76808-79-2 3,4-dimethyl-1,6-diphenyldipyrazolo<4,5-b:4',5'-c>-1,6-dihydropyridazine 

Relevant academic research and scientific papers

Metal-free ring opening of 5-amino-1,4-diaryl-1H-pyrazoles: A facile access to 2-aryl-3-arylazoacrylonitriles

Various 2-aryl-3-arylazoacrylonitriles are synthesized while attempting the intramolecular N-arylation of 5-aminopyrazoles, using the hypervalent iodine reagent. The synthesis involves phenyl iodine diacetate-assisted ring opening of 5-aminopyrazoles at r

PIDA-mediated oxidative aromatic C[sbnd]N bond cleavage: Efficient methodology for the synthesis of 1,2-diaza-1,3-dienes under ambient conditions

A series of functionalized 1,2-diaza-1,3-diene derivatives were synthesized from 5–aminopyrazoles via oxidative cleavage of the aromatic C[sbnd]N bond under transition metal-free conditions. A control experiment revealed that the presence of a free NHsub

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.